Últimas noticias sobre ProPhase Labs (NASDAQ:PRPH) Bolsa

ProPhase Labs

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

ProPhase Labs Inc

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 250 points on Friday.
The Dow traded up 0.62% to 44,001.69 while the NASDAQ fell 0.01% to 19,268.55. The S&amp;P 500 also rose, gaining, 0.40% to 5,997.19.
Check This Out: <a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a>
Leading and Lagging Sectors Utilities shares surged by 1.6% on Friday.
In trading on Friday, materials shares fell by 0.8%.
Top Headline
The University of Michigan consumer sentiment rose to 73 in November, recording the highest reading in seven months, versus a reading of 70.5 in October and also topping market estimates of 71.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) shares shot up 65% to $413.71 after the company reported a year-over-year increase in third-quarter financial results, raised its FY24 guidance, and issued FY25 adjusted EPS guidance above estimates.</li>
<li>Shares of Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) got a boost, surging 47% to $26.38 after the company reported better-than-expected third-quarter revenue results.</li>
<li>indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares were also up, gaining 46% to $5.02 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares dropped 46% to $0.7752 after the company reported the pricing of public offering of common stock.</li>
<li>Shares of Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) were down 43% to $13.94 after the company reported worse-than-expected third-quarter financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) was down, falling 34% to $0.0975 after the company announced a $3 million public offering.</li>
</ul>
Commodities In commodity news, oil traded down 2.7% to $70.40 while gold traded down 0.4% at $2,695.00.
Silver traded down 1.2% to $31.470 on Friday, while copper fell 2.9% to $4.3015.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.65%, Germany's DAX fell 0.76% and France's CAC 40 fell 1.17%. Spain's IBEX 35 Index fell 0.16%, while London's FTSE 100 fell 0.84%.
The trade gap in France increased to €8.3 billion in September versus a revised €7.7 billion gap in the previous month, while current account deficit increased to €2.1 billion in September.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng Index falling 1.07%, China's Shanghai Composite Index dipping 0.53% and India's BSE Sensex falling 0.07%.
Foreign exchange reserves held by the Reserve Bank of India declined to $682.1 billion as of Nov. 1. China reported a current account surplus of $149.6 billion during the third quarter compared to the $60.8 billion surplus in the year-ago period. Japan&#8217;s household spending declined by 1.1% year-over-year in September.
Economics
The University of Michigan consumer sentiment rose to 73 in November, recording the highest reading in seven months, versus a reading of 70.5 in October and also topping market estimates of 71.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/dividends/24/11/41843561/wall-streets-most-accurate-analysts-spotlight-on-3-tech-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech Stocks With Over 3% Dividend Yields</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AAOI

INDI

NMHI

PRPH

SEZL

Dow Tops 44,000; US Consumer Sentiment Increases In November

ProPhase Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares are trading lower by 47% to 75 cents during Friday&#8217;s session. The company announced an underwritten public offering of 4.17 million shares of common stock at 72 cents per share, totaling <a href="https://www.benzinga.com/pressreleases/24/11/g41833527/prophase-labs-announces-pricing-of-public-offering-of-common-stock">approximately $3 million</a> before expenses and discounts.
The company also granted underwriters a 45-day option to purchase up to an additional 625,500 shares to cover over-allotments. The offering, set to close on November 12, is managed by ThinkEquity. 
ProPhase Labs says proceeds will fund working capital and general corporate purposes, including capital investments, product development, commercialization and potential acquisitions in diagnostics, genomics and consumer products.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41843928/bitcoin-etfs-saw-record-1-38-billion-inflows-on-thursday">Bitcoin ETFs Saw Record $1.38 Billion Inflows On Thursday</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PRPH has a 52-week high of $7.48 and a 52-week low of $0.66.

Why ProPhase Labs (PRPH) Stock Is Down 47% Today

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock rose 39.8% to $0.36 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock increased by 33.57% to $24.11. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock moved upwards by 32.05% to $20.39. The market value of their outstanding shares is at $358.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares increased by 21.59% to $3.2. The company's market cap stands at $83.1 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 19.31% to $0.45. The market value of their outstanding shares is at $6.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock increased by 18.7% to $3.3. The company's market cap stands at $217.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 48.1% to $0.74 during Friday's regular session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 41.11% to $14.47. The company's market cap stands at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 37.31% to $4.92. The market value of their outstanding shares is at $695.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock fell 36.6% to $3.67. The company's market cap stands at $381.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 32.08% to $1.9. The market value of their outstanding shares is at $779.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock decreased by 29.23% to $0.69. The market value of their outstanding shares is at $80.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALVR

BNOX

FTRE

MRVI

NOTV

RIGL

RVNC

TIVC

12 Health Care Stocks Moving In Friday's Intraday Session

WIIM

ProPhase Labs shares are trading lower after the company announced a $3 million public offering of 4.17 million common shares at $0.72 per share.

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 0.2% on Friday.
Following the market opening Friday, the Dow traded up 0.20% to 43,817.98 while the NASDAQ fell 0.10% to 19,250.88. The S&amp;P 500 also rose, gaining, 0.13% to 5,981.13.
Check This Out: <a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a>
Leading and Lagging Sectors Utilities shares surged by 1% on Friday.
In trading on Friday, materials shares fell by 0.4%.
Top Headline
Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) reported worse-than-expected third-quarter financial results and cuts its FY24 adjusted EBITDA guidance.
Fluor reported quarterly earnings of 51 cents per share which missed the analyst consensus estimate of 76 cents per share. The company reported quarterly sales of $4.094 billion which missed the analyst consensus estimate of $4.738 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Northann Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCL#NYSE">NCL</a>) shares shot up 122% to $0.4977.</li>
<li>Shares of Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) got a boost, surging 93% to $0.5030. Tivic Health&#xAE; Systems will report financial results on Thursday, Nov. 14 after market close.</li>
<li>FOXO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>) shares were also up, gaining 66% to $0.6130.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares dropped 52% to $0.69 after the company reported the pricing of public offering of common stock.</li>
<li>Shares of Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) were down 42% to $14.34 after the company reported worse-than-expected third-quarter financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) was down, falling 40% to $0.0891 after the company announced a $3 million public offering.</li>
</ul>
Commodities In commodity news, oil traded down 1.2% to $71.47 while gold traded up 0.1% at $2,709.70.
Silver traded up 0.2% to $31.915 on Friday, while copper fell 2% to $4.3430.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.5%, Germany's DAX fell 0.7% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 fell 0.6%.
The trade gap in France increased to €8.3 billion in September versus a revised €7.7 billion gap in the previous month, while current account deficit increased to €2.1 billion in September.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng Index falling 1.07%, China's Shanghai Composite Index dipping 0.53% and India's BSE Sensex falling 0.07%.
Foreign exchange reserves held by the Reserve Bank of India declined to $682.1 billion as of Nov. 1. China reported a current account surplus of $149.6 billion during the third quarter compared to the $60.8 billion surplus in the year-ago period. Japan&#8217;s household spending declined by 1.1% year-over-year in September.
Economics
The University of Michigan consumer sentiment index will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/dividends/24/11/41843561/wall-streets-most-accurate-analysts-spotlight-on-3-tech-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech Stocks With Over 3% Dividend Yields</a></li>
</ul>

FOXO

Nuveen Insured California Premium Fund Ii

US Stocks Mixed; Fluor Earnings Miss Views

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares rose 127.3% to $0.59 during Friday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock moved upwards by 39.82% to $60.71. The market value of their outstanding shares is at $11.2 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 14.42% to $1.19. The market value of their outstanding shares is at $52.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 13.97% to $0.55. The market value of their outstanding shares is at $47.4 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares rose 13.68% to $20.52. The market value of their outstanding shares is at $1.8 billion. The company's, Q3 earnings came out today. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares moved upwards by 12.99% to $1.13. The market value of their outstanding shares is at $88.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares declined by 51.0% to $0.7 during Friday's pre-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock decreased by 35.5% to $15.85. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares fell 31.9% to $1.9. The company's market cap stands at $781.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares declined by 28.19% to $5.63. The market value of their outstanding shares is at $796.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares fell 15.23% to $4.9. The market value of their outstanding shares is at $510.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares fell 14.42% to $0.84. The company's market cap stands at $96.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTMX

DOCS

EYEN

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock moved upwards by 127.3% to $0.59 during Friday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares moved upwards by 39.82% to $60.71. The company's market cap stands at $11.2 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 14.42% to $1.19. The market value of their outstanding shares is at $52.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 13.97% to $0.55. The market value of their outstanding shares is at $47.4 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares increased by 13.68% to $20.52. The company's market cap stands at $1.8 billion. The company's, Q3 earnings came out today. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares increased by 12.99% to $1.13. The market value of their outstanding shares is at $88.2 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares fell 51.0% to $0.7 during Friday's pre-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 35.5% to $15.85. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 31.9% to $1.9. The market value of their outstanding shares is at $781.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 28.19% to $5.63. The company's market cap stands at $796.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock declined by 15.23% to $4.9. The market value of their outstanding shares is at $510.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares decreased by 14.42% to $0.84. The market value of their outstanding shares is at $96.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/11/41828267/upstart-stock-soars-after-strong-q3-results-details">third-quarter financial results</a>.
Upstart reported quarterly losses of seven cents per share which beat the analyst consensus estimate for losses of 15 cents. Quarterly revenue came in at $162.14 million which beat the analyst consensus estimate of $150.22 million and is an increase over sales of $134.55 million from the same period last year.
Upstart shares jumped 23.1% to $68.29 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) gained 370% to $4.85 in pre-market trading after dipping around 58% on Thursday.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 52.8% to $0.4010 in pre-market trading. Tivic Health&#xAE; Systems will report financial results on Thursday, Nov, 14, after the closing bell.</li>
<li>Doximity, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares surged 44.2% to $62.60 in pre-market trading following better-than-expected second-quarter financial results.</li>
<li>Li-Cycle Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) gained 41% to $5.09 in pre-market trading after posting upbeat quarterly results.</li>
<li>Northann Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCL#NYSE">NCL</a>) climbed 37.6% to $0.3089 in pre-market trading after jumping around 12% on Thursday.</li>
<li>Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares rose 36.4% to $33.20 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) gained 31.8% to $0.1953 in pre-market trading after jumping over 52% on Thursday.</li>
<li>Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) gained 24.6% to $40.88 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates.</li>
<li>Lumentum Holdings Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) gained 24.3% to $91.54 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares tumbled 45.4% to $0.7800 in pre-market trading after the company announced the pricing of public offering of common stock.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) shares fell 33.6% to $16.31 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>AtlasClear Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) dipped 31.8% to $0.1910 in pre-market trading after jumping over 55% on Thursday.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares fell 29% to $1.98 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) declined 26.6% to $5.75 in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance.</li>
<li>MDJM Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDJH#NASDAQ">MDJH</a>) shares dipped 22.4% to $0.1511 in pre-market trading after jumping 30% on Thursday.</li>
<li>Earlyworks Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) fell 17% to $5.60 in pre-market trading after surging over 10% on Thursday.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) fell 15% to $35.87 in today's pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) fell 14.1% to $9.85 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>Wag! Group Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PET#NYSE">PET</a>) fell 13.8% to $0.5487 in pre-market trading. Wag! will report third quarter 2024 financial results before the opening bell on Wednesday, Nov. 13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Pre-Market Outlook

ATCH

DEVS

ELWS

FIVN

INOD

LICY

LITE

MDJH

RDFN

UPST

Why Upstart Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital expenditures, product development and commercialization expenditures, and acquisitions of companies, businesses, technologies and products within and outside the diagnostic services, genomics and consumer products industry.

Reported Earlier, ProPhase Labs Prices $3M Public Offering Of 4.17M Common Shares At $0.72/Share

ProPhase Labs shares are trading lower after the company announced its intention to sell shares through a public offering.

Offerings

ProPhase Labs Announced That Intends To Sell Shares Of Its Common Stock In An Underwritten Public Offering; Terms Not Disclosed

Introduces DNA Expand Subscription Platform to Enrich Existing DNA Ancestry Data with Comprehensive Health Insights
GARDEN CITY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) (the "Company" or "ProPhase"), a next generation biotech, genomics, and diagnostics company, today announced the launch of DNA Complete, Inc., a wholly owned subsidiary, offering a groundbreaking direct-to-consumer DNA test that sequences virtually 100% of a customer's genome. This new service provides customers with in-depth insights into health, wellness, and ancestry.
DNA Complete – A New Paradigm in Direct-to-Consumer DNA Testing
<ul>
<li>Comprehensive Whole Genome Sequencing: Unlike traditional DNA Ancestry tests that analyze small snippets of DNA, DNA Complete offers a full genomic view, empowering customers with detailed health and wellness information alongside enhanced ancestry data.</li>
<li>Strategic Leadership Addition: ProPhase retained Stu Hollenshead, former Chief Business Officer and COO of Barstool Sports and current CEO of 10PMCurfew, to spearhead marketing efforts.</li>
<li>Influencer-Driven Marketing Campaign: A robust marketing initiative featuring top social media influencers is set to launch and aims to maximize reach and engagement.</li>
<li>Competitive Pricing and Robust Platform: DNA Complete is designed to offer a robust genetic user platform at competitive pricing which makes advanced genomic insights accessible to a wider audience.</li>
<li>Cutting-Edge Bioinformatics and Ancestry Analysis: The service leverages its advanced bioinformatics platform and introduces a proprietary, sophisticated ancestry platform.</li>
<li>Flexibility with Sample Processing: DNA Complete provides the flexibility to send samples to ProPhase Labs' other wholly owned subsidiary, Nebula Genomics, as well as other leading genetics labs, ensuring the highest quality results and efficient pricing and turnaround times.</li>
<li>Continuous Engagement Through Subscription: The DNA Complete subscription service ensures ongoing customer engagement by providing regular updates and new insights. The subscription model is a high margin business that we expect will create longer term cash flow.</li>
<li>Genetic Counseling Services: To enhance the value proposition, DNA Complete offers genetic counseling to help customers interpret their data effectively.</li>
</ul>
DNA Expand – Enhancing Existing DNA Ancestry Data
<ul>
<li>Effortless Data Upload: Consumers can easily upload their DNA data from other ancestry tests to unlock ProPhase's proprietary health and wellness reports.</li>
<li>Significant Data Expansion: Users' existing DNA files are amplified with 50 times more data than available through traditional DNA ancestry tests, delivering more in-depth insights without the need for additional sequencing.</li>
<li>Flexible Subscription Options: Monthly and yearly subscriptions are available, with new reports added regularly to keep customers informed.</li>
<li>Significant Target Market: A recent estimate indicates that more than 26 million people worldwide have undergone genetic ancestry testing by direct-to-consumer (DTC) companies.1</li>
<li>High Margins with Minimal Costs: We will offer a subscription at $49.95 annually. Since no new sequencing is required, the cost of goods sold is minimal (primarily the cost of IT) and the margins should be substantial. Over the next few years, with minimal market penetration we would therefore expect significant revenues, gross profit and longer-term cash flow. &nbsp;</li>
</ul>

Biotech

General

ProPhase Labs Launches DNA Complete, To Enrich Existing DNA Ancestry Data With Comprehensive Health Insights

<h2 class="wp-block-heading">New On The Block</h2>
Ari Emanuel&#8216;s sports and entertainment conglomerate, Endeavor Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>), is reviewing a potential sale of IMG tennis assets — including the Miami Open and Madrid Open tennis tournaments. Most of IMG&#8217;s other assets were included in a transaction announced on Thursday with TKO Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), the parent company of Ultimate Fighting Championship (UFC) and <a href="https://www.benzinga.com/topic/wwe">World Wrestling Entertainment (WWE)</a>. 
The Frieze Art Fair, a curated event featuring modern and contemporary works, is also for sale. Endeavor acquired a majority stake in April 2016. The Raine Group is advising Endeavor.
See Also: <a href="https://www.benzinga.com/government/24/10/41549838/uk-launches-antitrust-review-of-synopsys-34-billion-ansys-deal-over-growing-concerns">UK Launches Antitrust Review Of Synopsys&#8217; $34 Billion Ansys Deal Over Growing Concerns</a>
<h2 class="wp-block-heading">Off The Block</h2>
TKO, created a year ago from the <a href="https://www.benzinga.com/general/entertainment/23/09/34455843/wwe-and-ufc-merge-on-tuesday-heres-what-you-need-to-know">merger of the WWE and UFC</a>, acquired sports marketing agency IMG from Endeavor in a $3.25 billion all-equity deal that included Fort Worth, Texas-based Professional Bull Riders and live events business On Location. The sale is expected to close in the first half of 2025. Endeavor will end up owning approximately 59% of TKO. Separately, TKO's board has authorized a share-repurchase program of up to $2 billion of Class A common stock.
PPG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) agreed to sell its architectural coatings business in the U.S. and Canada for $550 million to private equity firm American Industrial Partners. This ends a sale process first announced in February. The transaction is expected to close in late 2024 or early 2025. Goldman Sachs &amp; Co. LLC advised PPG on the sale while law firm Hogan Lovells U.S. handled legal matters.
Jif peanut butter maker J.M. Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) jettisoned its cookie brand, Voortman, to snacks company Second Name Brands for $305 million. Reuters first reported about the auction in July. J.M. Smucker also owns Folgers coffee, Hostess baked snacks, and a variety of pet foods, such as Meow Mix and Kibbles &#8216;n Bits.
<h2 class="wp-block-heading">Updates From The Block</h2>
Biotech firm ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) <a href="https://www.nasdaq.com/press-release/prophase-labs-announces-positive-updates-strategic-initiatives-company-anticipates">engaged</a> ThinkEquity to advise the sale of PMI. So far, more than 70 potential acquirers are in consideration. The deal is expected to close in 2025.
Durham, North Carolina-based Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) <a href="https://www.ft.com/content/b31d96e7-9c1c-44d9-b358-ebe8ce7842c1">put</a> plans for a German semiconductor plant on hold. The development comes about two months after activist investment firm, Jana Partners, started urging the Wolfspeed board to explore a sale of the entire company.
Verizon Communications Inc. ((NYSE, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NASDAQ">VZ</a>) offered to buy Frontier Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FYBR#NASDAQ">FYBR</a>) for $38.50 per share. The Frontier board had been considering a sale; it recommended stockholders vote "for" the transaction.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Radford Motors, a luxury car manufacturer owned by British TV personality Ant Anstead, <a href="https://people.com/ant-anstead-supercar-company-radford-motors-files-for-bankruptcy-8733015">filed</a> Chapter 11. People Magazine broke the story. This year, Hiphi, a Chinese EV startup, backed by Human Horizons, filed for bankruptcy in August. E.Go, a German electric car maker, filed for insolvency for the second time in March and entered liquidation in May.
Now Read:
<ul>
<li><a href="EXCLUSIVE: Anthony Scaramucci Predicts 'Acceptance Of Stablecoins' As Digital Dollars With Upcoming Crypto-Friendly Congress">EXCLUSIVE: Anthony Scaramucci Predicts &#8216;Acceptance Of Stablecoins&#8217; As Digital Dollars With Upcoming Crypto-Friendly Congress</a></li>
</ul>

Asset Sales

BLCO

FYBR

WOLF

Deal Dispatch: UFC, WWE Parent TKO Takes On Bull Riding; Endeavor Looks To Sell Tennis; Another Car Company Goes Bankrupt

ProPhase Labs Announces Updates On Strategic Initiatives, Projects Pharmaloz Manufacturing 2025 Revenue Of $16-17M And Pre-Tax Earnings Of $6-7M, Targets PMI Sale In Early 2025 Valued Over $40M, And Engages In Strategic Partnership Talks For BE-Smart Esophageal Cancer Test With Potential Upfront Payment Of $30-50M

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.12) by 175 percent. This is a 1550 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $2.474 million which missed the analyst consensus estimate of $11.175 million by 77.86 percent. This is a 81.28 percent decrease over sales of $13.217 million the same period last year.

Earnings Misses

ProPhase Labs Q2 2024 GAAP EPS $(0.33) Misses $(0.12) Estimate, Sales $2.474M Miss $11.175M Estimate

PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. &nbsp;
New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value Creation
Garden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. ("PMI"), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025. The Company believes that the strategic enhancements to PMI's primary production line have generated increased capacity, revenue opportunities, efficiency as well as diversified and increased product offerings. These enhancements, combined with more favorable pricing, have led to a projected increase in PMI's revenues, margins and profitability going forward. Therefore, ProPhase believes there are several strategic options for PMI in 2024 and 2025 that may provide significant liquidity and value creation for the Company, though there can be no assurance that any transaction will occur. The Company has engaged ThinkEquity as an advisor to pursue strategic alternatives for PMI.
Based on these improvements and the expectation of continued increasing customer demand, the Company believes that beginning in the current Q3 2024, PMI's 12-month forward looking revenue run rate with one production line will be approximately $14-16 million and approximately $5 million in pre-tax net profits. These results are anticipated solely through operation of PMI's first enhanced manufacturing line. To place this in perspective, PMI generated approximately $9.3 million in revenues and reported net losses from operations in calendar year 2023.

Guidance

ProPhase Labs Announces Update On Pharmaloz Manufacturing Progress; Says PMI's 12-Month Forward Looking Revenue Run Rate With One Production Line Will Be ~$14M-16M And ~$5M In Pre-Tax Net Profits

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.18) by 61.11 percent. The company reported quarterly sales of $3.634 million which missed the analyst consensus estimate of $9.860 million by 63.14 percent. This is a 81.17 percent decrease over sales of $19.303 million the same period last year.

Earnings Beats

ProPhase Labs Q1 2024 GAAP EPS $(0.07) Beats $(0.18) Estimate, Sales $3.634M Miss $9.860M Estimate

Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. &nbsp;
Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS) spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests. Whole Genome Sequencing (WGS) offers an exhaustive exploration of an individual's entire DNA, capturing all three billion base pairs for a complete and detailed genetic blueprint. This comprehensive approach contrasts sharply with SNP tests, which target specific genetic variations at known locations, typically analyzing between 100,000 to 1 million specific points. With WGS providing up to 30,000 times more genetic data than SNP testing, our service delivers unparalleled precision in personalized medicine and genetic research, far beyond the scope of standard SNP testing. Along with the data gathered from the Company's BE-Smart Test for esophageal adenocarcinoma (EAC), the platform is being utilized to create algorithms that identify possible antibody drug conjugate (ADC) candidates for new cancer therapeutics.
Antibody drug conjugates (ADCs) are specialized treatments that differ from traditional chemotherapy by specifically targeting cancer cells. ADCs use a linker to attach chemotherapy agents to a monoclonal antibody, which then binds to a unique marker found on the surface of cancer cells. This targeted approach helps to minimize damage to healthy cells and other side effects. ADCs represent a potent class of cancer therapies, blending the specificity of monoclonal antibodies with cytotoxic drugs. Leveraging ZenQ-AI with both genomic and proteomic data is believed to enable the rapid identification of biomarkers and mutations driving cancer, streamlining the design of ADCs for precise targeting. This integration promises more effective and personalized treatments, though rigorous experimental validation remains crucial for ensuring safety and efficacy of new therapeutic candidates.
"The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we've curated and continue to grow," explained Ted Karkus, CEO at ProPhase Labs. "This unique combination of sophisticated AI and rich, diverse genomic and proteomic data sources enhances our approach to cancer treatment as both innovative and effective."

ProPhase Labs Unveils Project ZenQ-AI; Leveraging ProPhase Labs' AI Platform, Massive Genomics Database And Patented Esophageal Cancer Insights For Antibody Drug Conjugates Development

ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. &nbsp;
Ted Karkus, CEO of ProPhase Labs, commented, "The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection. Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future. This groundbreaking diagnostic test is a patent-protected method for identifying esophageal cancer markers and a key component of ProPhase Labs' mission to enhance early detection and facilitate personalized treatment strategies and reflects our commitment to saving lives and improving patient care."
The BE-Smart test constitutes a major innovation in the detection and management of esophageal adenocarcinoma ("EAC") and stands at the forefront of a diagnostic revolution. ProPhase intends to pursue and seeks to capture a significant share of a multi-billion-dollar market for EAC diagnostics. The Company anticipates reimbursement rates ranging between $1,000 and $2,000 per test based on CPT codes (as defined below) of similarly complex tests[1]. By addressing the annual estimated demand for 7 million endoscopies in the U.S. alone for severe GERD and Barrett's Esophagus cases, the BE-Smart test targets an initial market size of $7 billion to $14 billion.
ProPhase Labs, in collaboration with mProbe Inc., a precision health and medicine company utilizing clinical proteomics in the oncology space, is nearing completion of rigorous validation studies of the BE-Smart test, which at its core aims to accurately implement our patent-protected method for identifying esophageal cancer markers. This phase of analytical validation is being completed in parallel with clinical verification by institutions including the Mayo Clinic and Genesis Clinical, a leader in statistical analysis and algorithm development.
"Once completed, we anticipate that the analytical validation studies will demonstrate to the scientific and medical community the BE-Smart test's reliability, accuracy, and readiness for widespread clinical use," said Igor Ban, PhD, director of Research and Development at ProPhase. "Understanding the critical role of extensive data in improving diagnostic tools, we are reaching out to research hospitals across the US and Europe to form partnerships. These collaborations will provide BE-Smart with access to a wider array of esophageal tissue samples, including those from diverse patient demographics and various stages of Barrett's Esophagus and EAC. Following commercialization, this invaluable data pool will enable BE-Smart to conduct more nuanced analyses, continuously advancing the test's sensitivity, specificity, and overall utility."
Within the coming months, the Company anticipates submitting the documentation required for BE-Smart's Advanced Diagnostic Laboratory Test (ADLT) application, a subclass of the Current Procedural Terminology ("CPT") Proprietary Laboratory Analyses ("PLA") coding system. ProPhase plans to commercially launch BE-Smart following CPT code approval, which is anticipated in the second half of 2024, paving the way for a new era in cancer diagnostics.
Obtaining CPT codes is important for billing purposes, enabling ProPhase Labs to bill for providing the test services and receive reimbursement from insurance companies. The Company is diligently preparing and compiling all necessary documentation to ensure compliance with regulatory standards.
Developed over six years, the BE-Smart test leverages sophisticated proteomics to improve early detection of EAC, a valuable tool given that EAC is among the deadliest cancers with no effective currently available targeted treatments. This unfortunate situation, where approximately 80-90% of EAC patients face a fatal outcome, highlights the important need for a groundbreaking diagnostic tool like BE-Smart.
Through its partnership with Genesis Clinical, the Company is bolstering BE-Smart's capability to stratify esophageal cancer risk accurately, a development of immense value to patients and insurance providers. The test's innovative approach not only promises early detection but also promises to stratify patients into low or high-risk groups with remarkable accuracy.
Mr. Karkus continued, "This risk assessment is crucial, offering peace of mind to those at low risk and potentially sparing them from unnecessary and costly annual endoscopies. For high-risk individuals, it facilitates timely interventions, such as ablation procedures reimbursed by insurance, offering a lifesaving and cost-effective solution compared to the management of advanced disease. Being able to provide targeted patient care strategies, we believe that the BE-Smart test stands at the forefront of transforming patient management in EAC, embodying a holistic approach to enhancing patient outcomes through state-of-the-art early detection and personalized care plans. And the beauty of the test is that it is performed on slivers of tissue specimens that are already being extracted during routine endoscopy procedures."

ProPhase Labs Seeks To Transform Esophageal Cancer Detection And Management With Launch Of Its BE-Smart Test In H2 2024

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.26) by 96.15 percent. This is a 537.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $4.35 million which missed the analyst consensus estimate of $10.69 million by 59.30 percent. This is a 80.06 percent decrease over sales of $21.82 million the same period last year.

ProPhase Labs Q4 EPS $(0.51) Misses $(0.26) Estimate, Sales $4.35M Miss $10.69M Estimate

Here's the major earnings before the open tomorrow

ProPhase Labs misses Q2 estimates

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ProPhase Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/prph-stock-quote/">PRPH</a>) just reported results for the second quarter of 2024.<ul><li>ProPhase Labs reported earnings per share of -33 cents. This was below the analyst estimate for EPS of -24 cents.</li><li>The company reported revenue of $2.47 million.</li><li>This was 77.85% worse than the analyst estimate for revenue of $11.17 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/prph-stock-earnings-prophase-labs-for-q2-of-2024/">PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q2 2024

ProPhase Labs, Inc. (PRPH) Q2 2024 Earnings Call Transcript

ProPhase Labs, Inc. 2024 Q2 - Results - Earnings Call Presentation

The latest update is out from Prophase Labs ( ($PRPH) ). ProPhase Labs, Inc. has fallen out of compliance with Nasdaq's audit committee requirement...

ProPhase Labs Seeks Director Amidst Nasdaq Compliance Issue

ProPhase Labs (PRPH) announced the launch of DNA Complete, offering a direct-to-consumer DNA test that sequences virtually 100% of a customer's gen...

ProPhase Labs launches DNA Complete, a direct-to-consumer DNA test

ProPhase Labs announces proposed public offering of common stock

ProPhase Labs plummets 21%, prices $3M equity offering

ThinkEquity acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving break...

ProPhase Labs 4.17M share Spot Secondary priced at $.72

ARCO

BCLI

BKKT

BLUE

CRMD

DOLE

EONGY

ESLT

FLNG

GLBE

HNHAF

IMNN

IPWR

ITRM

KMDA

KPLT

MDWD

MEDIF

MGIC

ONDS

OTLK

PFGC

POAI

RSKD

SACH

SUNS

TCEHY

TSAT

VISL

VWDRY

WKHS

Press Releases

ProPhase Labs Announces Collaboration with Forward Healthcare Consultants to Aid in the Commercialization of its Billion Dollar Potential BE-Smart Esophageal Cancer Test

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024

ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event

Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025

ProPhase Labs to Present at the 2024 ThinkEquity Conference

Health Care

ProPhase Labs Launches DNA Complete®: Transforming Direct-to-Consumer Genetic Testing for Health, Wellness, and Enhanced Ancestry

Comments

ProPhase Labs

Noticias

Últimas noticias sobre ProPhase Labs (NASDAQ:PRPH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL